Table 1.

Patient demographic and tumor profile (N=100)

Characteristics	Frequency (%)
Age(years) median	30 years (IQR: 21-41.65)
Gender
Male	69 (69%)
Female	31 (31%)
Histological variants
Lymphocyte Rich	3 (3%)
CHL- Mixed Cellularity	26 (26%)
CHL- Nodular Sclerosis	27 (27%)
Not classified	36 (36%)
Nodular Lymphocyte Predominant	8 (8%)
Stage
III	52 (52%)
IV	48 (48%)
Bulky Disease
Yes	39 (39%)
No	61 (61%)
‘B’ Symptoms
Yes	62 (62%)
No	38 (38%)
International Prognostic Score (IPS)
Low risk (0-2)	44 (44%)
Intermediate risk (3-4)	49 (49%)
High risk (5-7)	7 (7%)

Abbreviations: IQR, Inter-Quartile Range